5-(2-benzo[b]thienyl)-2-morpholinopyrimidine | 887413-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 5-(2-benzo[b]thienyl)-2-morpholinopyrimidine
• 英文别名: 4-(5-(benzo[b]thiophen-2-yl)pyrimidin-2-yl)morpholine；4-[5-(1-Benzothiophen-2-yl)pyrimidin-2-yl]morpholine
• CAS: 887413-59-4
• 化学式: C₁₆H₁₅N₃OS
• 分子量: 297.381
• InChiKey: LCXGDQSFZUELPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(嘧啶-2-基)吗啉 在 四(三苯基膦)钯 、 溴 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 1.33h， 生成 5-(2-benzo[b]thienyl)-2-morpholinopyrimidine
  参考文献：
  名称：

  Synthesis of 5-(het)aryl- and 4,5-di(het)aryl-2-(thio)morpholinopyrimidines from 2-chloropyrimidine via SN H and cross-coupling reactions

  摘要：

  研究表明，利用氢的亲核芳香取代反应（SN H）、SN ipso反应以及微波辅助的铃木交叉耦合反应的各种组合，是一种多功能的合成方法，可用于制备5-（杂）芳基-2-（硫）吗啉基嘧啶和4,5-二（杂）芳基-2-（硫）吗啉基嘧啶衍生物。所有合成的嘧啶在体外对结核杆菌H37Rv均表现出微摩尔浓度水平的活性。

  DOI：

  10.1007/s11172-014-0602-y

文献信息

• Novel 2-Heteroaryl Substituted Benzothiophenes and Benzofuranes 709
  申请人：Arzel Erwan

  公开号：US20080221149A1

  公开（公告）日：2008-09-11

  The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measureing clinical efficacy of Alzheimer's disease therapeutic agents.

  本发明涉及新型2-杂环芳基取代苯并噻吩和苯并呋喃衍生物，其前体以及这些化合物的治疗用途，具有如下结构式(Ia)： 以及它们的药用盐、组合物和使用方法。此外，本发明涉及适用于在活体患者中成像淀粉样沉积物的新型2-杂环芳基取代苯并噻吩和苯并呋喃衍生物，它们的组合物、使用方法以及制备这类化合物的过程。更具体地，本发明涉及一种在体内成像脑部淀粉样沉积物的方法，以允许在死前诊断阿尔茨海默病，并测量阿尔茨海默病治疗药物的临床疗效。
• Introducing Savie: A Biodegradable Surfactant Enabling Chemo- and Biocatalysis and Related Reactions in Recyclable Water
  作者：Joseph R. A. Kincaid、Madison J. Wong、Nnamdi Akporji、Fabrice Gallou、David M. Fialho、Bruce H. Lipshutz

  DOI：10.1021/jacs.2c13444

  日期：——

  organic synthesis in recyclable water. This includes homogeneous catalysis (including examples employing only ppm levels of catalyst), heterogeneous catalysis, and biocatalytic transformations, including a multistep chemoenzymatic sequence. Use of Savie frequently leads to significantly higher yields than do conventional surfactants, while obviating the need for waste-generating organic solvents.

  Savie 是一种可生物降解的表面活性剂，源自维生素 E 和聚肌氨酸 (PSar)，开发用于可循环水中的有机合成。这包括均相催化（包括仅使用 ppm 级催化剂的例子）、多相催化和生物催化转化，包括多步化学酶序列。使用 Savie 通常会比传统表面活性剂产生显着更高的产率，同时无需使用产生废物的有机溶剂。
• Compounds that enhance Atoh-1 expression
  申请人：MASSACHUSETTS EYE & EAR INFIRMARY

  公开号：EP2732819A2

  公开（公告）日：2014-05-21

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g. a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

  本发明一般提供化合物、药物组合物及其使用方法，其中包括导致生物细胞中 Atoh1 基因（如 Hath1）表达增加的方法。更具体地说，本发明涉及可从 Atoh1 表达增加中获益的疾病和/或失调症的治疗，例如与听觉毛细胞丧失有关的听力损伤或失调症，或与细胞异常增殖有关的失调症。
• Compounds that enhance Atoh1 expression
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：US10406163B2

  公开（公告）日：2019-09-10

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

  本发明一般提供化合物、药物组合物及其使用方法，其中包括导致生物细胞中Atoh1基因（如Hath1）表达增加的方法。更具体地说，本发明涉及可从 Atoh1 表达增加中获益的疾病和/或失调症的治疗，例如，与听觉毛细胞丧失有关的听力损伤或失调症，或与细胞异常增殖有关的失调症。
• Efficient delivery of therapeutic molecules to cells of the inner ear
  申请人：Massachusetts Eye and Ear Infirmary

  公开号：US11370823B2

  公开（公告）日：2022-06-28

  Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

  提供了诱导内耳细胞进入细胞周期和增殖的组合物。特别是，通过服用能激活 Myc 和 Notch 的组合物来诱导毛细胞增殖。通过抑制 Myc 和 Notch 的活性或激活 Atoh1，诱导支持细胞向毛细胞转分化。治疗方法包括在细胞内将这些分子输送到特定的治疗靶点。